Latest Insider Transactions at Intra Cellular Therapies, Inc. (ITCI)
This section provides a real-time view of insider transactions for Intra Cellular Therapies, Inc. (ITCI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Intra-Cellular Therapies, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Intra-Cellular Therapies, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2025
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,729
-11.61%
|
$600,583
$127.0 P/Share
|
|
Jan 31
2025
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,017
+21.3%
|
-
|
|
Jan 31
2025
|
Michael Halstead President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,691
-51.66%
|
$722,757
$127.0 P/Share
|
|
Jan 31
2025
|
Michael Halstead President |
BUY
Grant, award, or other acquisition
|
Direct |
11,017
+50.0%
|
-
|
|
Jan 31
2025
|
Sharon Mates Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,233
-1.38%
|
$1,934,591
$127.0 P/Share
|
|
Jan 31
2025
|
Sharon Mates Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
30,847
+2.72%
|
-
|
|
Jan 31
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,730
-15.35%
|
$600,710
$127.0 P/Share
|
|
Jan 31
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,017
+26.33%
|
-
|
|
Dec 31
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
215
+0.16%
|
$17,845
$83.52 P/Share
|
|
Dec 05
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
51,697
-2.31%
|
$4,342,548
$84.38 P/Share
|
|
Dec 05
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
51,697
+4.4%
|
$620,364
$12.73 P/Share
|
|
Dec 04
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
51,000
-2.3%
|
$4,335,000
$85.81 P/Share
|
|
Dec 04
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
51,000
+4.35%
|
$612,000
$12.73 P/Share
|
|
Nov 13
2024
|
Michael Halstead President |
SELL
Open market or private sale
|
Direct |
18,714
-85.72%
|
$1,646,832
$88.54 P/Share
|
|
Nov 13
2024
|
Michael Halstead President |
BUY
Exercise of conversion of derivative security
|
Direct |
18,714
+50.0%
|
$673,704
$36.89 P/Share
|
|
Nov 12
2024
|
Michael Halstead President |
SELL
Open market or private sale
|
Direct |
22,869
-81.61%
|
$2,035,341
$89.75 P/Share
|
|
Nov 12
2024
|
Michael Halstead President |
BUY
Exercise of conversion of derivative security
|
Direct |
22,869
+50.0%
|
$525,987
$23.94 P/Share
|
|
Sep 30
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
246
+0.21%
|
$17,958
$73.17 P/Share
|
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
34,396
-1.56%
|
$2,510,908
$73.03 P/Share
|
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,396
+3.02%
|
$412,752
$12.73 P/Share
|
|
Aug 29
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
35,604
-1.62%
|
$2,563,488
$72.85 P/Share
|
|
Aug 29
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,604
+3.12%
|
$427,248
$12.73 P/Share
|
|
Aug 28
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
32,699
-1.48%
|
$2,387,027
$73.22 P/Share
|
|
Aug 28
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,699
+2.88%
|
$555,883
$17.57 P/Share
|
|
Aug 27
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
40,513
-1.84%
|
$2,957,449
$73.63 P/Share
|
|
Aug 27
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,513
+3.52%
|
$688,721
$17.57 P/Share
|
|
Aug 26
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
22,713
-2.08%
|
$1,680,762
$74.59 P/Share
|
|
Aug 26
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,713
+2.04%
|
$386,121
$17.57 P/Share
|
|
Aug 23
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
28,680
-2.61%
|
$2,122,320
$74.46 P/Share
|
|
Aug 23
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,680
+2.54%
|
$487,560
$17.57 P/Share
|
|
Aug 22
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
39,380
-1.78%
|
$2,953,500
$75.03 P/Share
|
|
Aug 22
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
39,380
+3.43%
|
$669,460
$17.57 P/Share
|
|
Aug 21
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
53,013
-1.19%
|
$4,028,988
$76.7 P/Share
|
|
Aug 21
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,013
+4.51%
|
$901,221
$17.57 P/Share
|
|
Aug 16
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
18,714
-38.65%
|
$1,403,550
$75.08 P/Share
|
|
Aug 16
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,714
+27.88%
|
$673,704
$36.89 P/Share
|
|
Jun 28
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
262
+0.22%
|
$17,816
$68.49 P/Share
|
|
Jun 28
2024
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
83
+0.73%
|
$5,644
$68.49 P/Share
|
|
Jun 24
2024
|
Rory B Riggs |
SELL
Open market or private sale
|
Direct |
4,462
-3.69%
|
$334,650
$75.57 P/Share
|
|
Jun 24
2024
|
Rory B Riggs |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+14.18%
|
$320,000
$16.86 P/Share
|
|
Jun 23
2024
|
Rory B Riggs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,567
+1.53%
|
-
|
|
Jun 23
2024
|
Joel S Marcus |
BUY
Exercise of conversion of derivative security
|
Direct |
1,567
+3.66%
|
-
|
|
Jun 23
2024
|
Eduardo Rene Salas |
BUY
Exercise of conversion of derivative security
|
Direct |
1,567
+50.0%
|
-
|
|
Jun 23
2024
|
Robert L Van Nostrand |
BUY
Exercise of conversion of derivative security
|
Direct |
1,567
+12.22%
|
-
|
|
Jun 18
2024
|
Robert L Van Nostrand |
SELL
Open market or private sale
|
Direct |
20,000
-41.68%
|
$1,500,000
$75.89 P/Share
|
|
Jun 18
2024
|
Robert L Van Nostrand |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+40.25%
|
$320,000
$16.86 P/Share
|
|
Apr 24
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,020
+0.93%
|
$340,340
$17.22 P/Share
|
|
Mar 31
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
260
+0.26%
|
$17,940
$69.2 P/Share
|
|
Mar 31
2024
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
79
+0.81%
|
$5,451
$69.2 P/Share
|
|
Mar 20
2024
|
Rory B Riggs |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.77%
|
$360,000
$18.56 P/Share
|